Published 3 days ago • loading... • Updated 3 days ago

Monoclonal Antibody Reduces Mortality for SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Summary by contagionlive.com

InflaRx CEO Niels Riedemann, MD, offers insights on his company’s monoclonal antibody, which demonstrated a nearly 24% reduction in 28 day all-cause mortality.

1 Articles

All

Left

Center

Right

contagionlive.com

Monoclonal Antibody Reduces Mortality for SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx CEO Niels Riedemann, MD, offers insights on his company’s monoclonal antibody, which demonstrated a nearly 24% reduction in 28 day all-cause mortality.

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated3 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contagionlive.com broke the news in 3 days ago on Wednesday, February 19, 2025.

Sources are mostly out of (0)

Monoclonal Antibody Reduces Mortality for SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

1 Articles

1 Articles

Monoclonal Antibody Reduces Mortality for SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Monoclonal Antibody Reduces Mortality for SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics